Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

GILEAD HEIGHTENS INFLAMMATORY DISEASE FOCUS WITH SECOND GENOME MICROBIOME DEAL

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

ORGANOVO FUTURE UNCLEAR AFTER SHAREHOLDERS REJECT TARVEDA MERGER

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking...

 
 
 
Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

KEROS THERAPEUTICS RAISES $96M IN UPSIZED IPO TO FUEL CLINICAL TESTS

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had...

 
 
 
Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

SAGE RESTRUCTURING HALVES STAFF, TURNS FOCUS TO FAILED DEPRESSION DRUG

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

INOVIO BEGINS EXPERIMENTAL COVID-19 VACCINE TESTS IN HEALTHY VOLUNTEERS

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its...

 
 
 
Creating Consistent Value in Biotech Without Diluting Stakeholders

CREATING CONSISTENT VALUE IN BIOTECH WITHOUT DILUTING STAKEHOLDERS

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

INTERACTIVE, ONLINE XCELERATING LIFE SCIENCES BOSTON EVENT SET FOR MAY 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial,...

 
 
 
Menlo's Itching Drug Racks Up Two More Trial Failures, Program Ends

MENLO'S ITCHING DRUG RACKS UP TWO MORE TRIAL FAILURES, PROGRAM ENDS

An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies,...

Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test

MILLENDO MAY RESTRUCTURE AFTER PRADER-WILLI DRUG FAILS PIVOTAL TEST

Millendo Therapeutics is considering a corporate reorganization after its lead drug, an investigational treatment for a rare genetic...

 
 
 
Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment

XCONOMY RELEASES CORONAVIRUS SPECIAL REPORT ON CONTAINING THE PANDEMIC THROUGH INNOVATION & INVESTMENT

Based on the latest news and analysis, as well as conversations from industry experts during the Combatting Coronavirus live panel...

 
 
 
Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies

FATE INKS $100M DEAL WITH JANSSEN FOR STEM CELL-DERIVED CANCER THERAPIES

Fate Therapeutics has signed an agreement with Janssen Biotech to develop new cancer cell therapies that are derived from stem cells...

Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic

DYNACURE ADDS $55M AS RNA-TARGETED MUSCLE DISORDER DRUG ENTERS CLINIC

Last month French biotech Dynacure dosed the first patient in an early-stage trial of its lead drug candidate, a treatment for a group...

 
 
 
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs

VENBIO PARTNERS BAGS $394M TO BACK MORE MEDICINE-MAKING BIOTECHS

Investors worried about a recession like venBio Partners' risk-mitigated approach to venture capital investing. That approach has led...

Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma's Path & More

BIO ROUNDUP: BIOTECH BILLIONS, COVID-19 R&D, ZOLGENSMA'S PATH & MORE

The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds...

 
 
 
Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials

ZENTALIS UPSIZES IPO, RAISING $165M FOR CANCER DRUG CLINICAL TRIALS

The global economic crash means the window for initial public stock offerings is all but closed but that didn't stop Zentalis Phamaceuticals...

 
 
 
Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID

CELULARITY TO TEST NATURAL KILLER CELL THERAPY FOR CANCER AGAINST COVID

Celularity, a New Jersey company developing experimental cancer treatments derived from human placentas, has received the FDA's blessing...

Vir Advances Antibodies Against COVID-19, CEO Leads BIO's Coronavirus Outreach

VIR ADVANCES ANTIBODIES AGAINST COVID-19, CEO LEADS BIO'S CORONAVIRUS OUTREACH

Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches...

 
 
 



World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the... Read more ...

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is... Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

Organovo Future Unclear After Shareholders Reject Tarveda Merger

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a... Read more ...

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

Image by Miroslava Chrienova from Pixabay Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic... Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis... Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The... Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including... Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

Creating Consistent Value in Biotech Without Diluting Stakeholders

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide... Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us... Read more ...

Methylation-driven model for analysis of dinucleotide evolution in genomes

CpGs, the major methylation sites in vertebrate genomes, exhibit a high mutation rate from the methylated form of CpG to TpG/CpA and, therefore, influence the evolution of... Read more ...